Novo Nordisk continues to soar as it brings in 166 billion DKK in turnover for the first nine months of this year

In a press release, the Danish pharmaceutical company well known for its weight loss and diabetes drugs, Ozempic and Wegovy, said the latest figures showed that they’ve had a 29% increase when compared to the same period last year. This was due to strong sales in North America, which have grown by 46%. Company president and CEO Lars Fruergaard Jørgensen said, “We are very satisfied with the sales growth in the first nine months of 2023, which is reflecting that more people than ever are benefiting from our innovative diabetes and obesity treatments.”